Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Fusen Pharmaceutical Co., Ltd. has announced that its Piracetam Injection, aimed at treating memory loss and brain dysfunction, has been accepted by China’s National Medical Products Administration. This drug is part of a growing market for neurological medications and could significantly expand Fusen’s offerings in cerebrovascular and cognitive treatment. With sales in public medical institutions reaching RMB2.0 billion in 2023, the potential for Piracetam Injection is substantial.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue